CETP inhibition improves the lipid profile but has no effect on clinical cardiovascular outcomes in high-risk patients
- PMID: 28844064
- DOI: 10.1136/ebmed-2017-110791
CETP inhibition improves the lipid profile but has no effect on clinical cardiovascular outcomes in high-risk patients
Keywords: clinical trials; ischaemic heart disease.
Conflict of interest statement
Competing interests: RR received funding for a steering committee on the use of PCSK9 inhibitors in familial hypercholesterolaemia for Eli Lilly. This development program was terminated earlier this year.
Comment on
-
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581. N Engl J Med. 2017. PMID: 28514624 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical